Sartar Therapeutics
PrivateLast Round
Early Funding
Oct 1, 2025
Est. Valuation
$15.59M
Total Funding Raised
$9.36M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Sartar Therapeutics is a pharmaceutical company that develops precision cancer treatments for gastrointestinal stromal tumors and other soft tissue sarcomas.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Sartar Therapeutics Comparables
Compare Sartar Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| GSK plc | 74% | |
| Amira Therapeutics | 74% | |
| Degron Therapeutics | 72% |
Sartar Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Early Funding | Oct 1, 2025 | ||||
| Debt | Sep 20, 2021 | ||||
| Seed | Oct 19, 2020 |
Key People
Founding team and executive leadership
Sartar Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Excedea Capital | Early Funding |
| Business Finland | Debt |
| Health Incubator Helsinki | Seed |
| NOME | Seed |
| Springvest | Early Funding, Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors grew 185% MoM, reaching 1K.
- Mar 1, 2026
Monthly visitors grew 961% MoM, from 67 to 711.
Sartar Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Sartar Therapeutics's valuation, stock price, and market status.
Is Sartar Therapeutics a public or private company?
Sartar Therapeutics is a private company.
What is the current stock price of Sartar Therapeutics?
Sartar Therapeutics is a private company with no public stock price. Caplight tracks Sartar Therapeutics's secondary market activity and provides MarketPrice™ estimates to Caplight users.
How much is Sartar Therapeutics worth (valuation)?
Sartar Therapeutics's valuation is estimated at $15.6M based on funding round data.
Can I buy Sartar Therapeutics stock?
Sartar Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Sartar Therapeutics's last funding round?
Sartar Therapeutics's most recent funding round was Early Funding on October 1, 2025.
Who are the main investors in Sartar Therapeutics?
Key investors in Sartar Therapeutics include Excedea Capital, Business Finland, Health Incubator Helsinki, NOME, Springvest.
Will Sartar Therapeutics IPO soon?
No public IPO plans have been announced for Sartar Therapeutics.
How can I track Sartar Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Sartar Therapeutics's secondary market activity and sign up for updates.